

References QBRI Insights: The Biology of SARS-CoV-2

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *The New England journal of medicine*. 2020;382(8):727-33.
2. Weiss SR, Leibowitz JL. Coronavirus pathogenesis. *Advances in virus research*. 2011;81:85-164.
3. de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. Host Factors in Coronavirus Replication. *Current topics in microbiology and immunology*. 2018;419:1-42.
4. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. 2020;181(2):271-80 e8.
5. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. *Circulation research*. 2000;87(5):E1-9.
6. Kuba K, Imai Y, Ohto-Nakanishi T, Penninger JM. Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. *Pharmacology & therapeutics*. 2010;128(1):119-28.
7. Jiang F, Yang J, Zhang Y, Dong M, Wang S, Zhang Q, et al. Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. *Nature reviews Cardiology*. 2014;11(7):413-26.
8. Lukassen S, Chua RL, Trefzer T, Kahn NC, Schneider MA, Muley T, et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. *The EMBO journal*. 2020:e105114.
9. Arpaia N, Barton GM. Toll-like receptors: key players in antiviral immunity. *Current opinion in virology*. 2011;1(6):447-54.
10. Zhou Y, He C, Wang L, Ge B. Post-translational regulation of antiviral innate signaling. *European journal of immunology*. 2017;47(9):1414-26.
11. Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, et al. Diagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus-2: A Narrative Review. *Annals of Internal Medicine*. 2020.



12. Corman V BT, Brünink S, Drosten C, Landt O, Koopmans M, et al. Diagnostic detection of Wuhan coronavirus 2019 by real-time RTPCR 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/wuhan-virus-assayv1991527e5122341d99287a1b17c111902.pdf?sfvrsn=d381fc88_2. [17 January 2020].
13. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*. 2020;25(3):2000045.
14. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *The Lancet Infectious Diseases*. 2020.
15. Andersen PI, Ianevski A, Lysvand H, Vitkauskiene A, Oksenysh V, Bjoras M, et al. Discovery and development of safe-in-man broad-spectrum antiviral agents. *Int J Infect Dis*. 2020;93:268-76.
16. Li H, Zhou Y, Zhang M, Wang H, Zhao Q, Liu J. Updated approaches against SARS-CoV-2. *Antimicrobial agents and chemotherapy*. 2020.
17. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta Pharm Sin B*. 2020.
18. Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of M(pro) from COVID-19 virus and discovery of its inhibitors. *Nature*. 2020.